[8:00-9:15] Session VII

Prognostic and Predictive Markers

Prashant Kapoor, Efstathios Kastritis [Chairs]

Models-Risk Stratification of Asymptomatic WM

Romanos Sklavenitis-Pistofidis, Dana Farber Cancer Institute, USA

Predictors of Short Survival in WM

Prashant Kapoor, Mayo Clinic, USA

Impact of 6q on WM clinical outcomes

Ramón García-Sanz, University of Salamanca, Spain

CXCR4 subtype and clonality impact ibrutinib response

Joshua Gustine, Dana Farber Cancer Institute, USA

Prognostic Impact of MYD88 L265P by ddPCR

Carlos Fernández de Larrea Rodríguez, Hospital Clinic Barcelona, Spain

[9:00] Panel Discussion, All Session VII Speakers

[9:15-10:45] Session VIII

Chemoimmunotherapy

Veronique Leblond, Jorge Castillo [Chairs]       

B-RCD vs. RCD Randomized Trial in WM

Pierre Morel, Centre Hospitalier Universitaire Amiens Picardie, France

RCD vs BCD Randomized Trial

Lugui Qiu, National Clinical Research Center for Blood Diseases, China

Bendamustine/Rituximab: Dose Intensity and Patient Outcomes

Suzanne Arulogun, UC London Hospitals NHS, UK

FILO Bendamustine Rituximab Study

Véronique Leblond, Hôpital Pitié Salpêtrière, France

STIL Maintenance Rituximab

Mathias Rummel, University of Giessen, Germany

BRB: Bendamustine, Rituximab, Bortezomib Study: Fondazione Italiana Linfomi Study

Giulia Benevolo, University of Torino, Italy

[10:30] Panel Discussion, All Session VIII Speakers

[10:45-11:15] Morning Break

[11:15-12:30] Session IX

BTK-Inhibitors I

Judith Trotman, Meletios Dimopoulos [Chairs]

Long Term Follow-Up of Ibrutinib Monotherapy in WM

Jorge Castillo, Dana Farber Cancer Institute, USA

Long Term Follow-up of the INNOVATE Study

Christian Buske, University Hospital Ulm, Germany

Comparative outcomes of Ibrutinib and Bendamustine in treatment naïve patients

Jithma Abeykoon, Mayo Clinic, USA

Real World Experiences with Ibrutinib-UK experience

Shirley D’Sa, UC London Hospitals NHS, UK

Real World Data on CIT and BTK-inhibitors: WHIMSICAL Study

Ibrahim Tohidi-Esfahani, University of Sydney, Australia

[12:15] Panel Discussion, All Session IX Speakers

[12:30-13:30] LUNCH

[13:30-14:30] Session X

BTK-Inhibitors II

Alessandra Tedeschi, Constantine Tam [Chairs]

Long Term Follow-up-Acalabrutinib Phase II

Roger Owen, Leeds Hospital NHS Trust, UK

Long Term Follow-Up Zanubrutinib-Phase II

Judith Trotman, University of Sydney, Australia

Phase II Zanubrutinib in relapsed/refractory WM: Chinese experience

Lugui Qui, National Clinical Research Center for Blood Diseases, China

Phase II study of Zanubrutinib, Ixazomib and Dexamethasone

Shuhua Yi, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

[14:15] Panel Discussion, All Session X Speakers

[14:30-15:30] Session: XI

Plenary Session II

M.J. Kersten, Christian Buske [Chairs]

WM004 Final results of the Phase I/II Hovon 124/ECWM-R2 Study including 2 year rituximab maintenance after induction with ixazomib, rituximab and dexamethasone in relapsed Waldenstrom’s Macroglobulinemia.

Karima Amaador, UMC Medical Center, University of Amsterdam, Netherlands

WM042 ASPEN: Long term follow-up results of a Phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenstrom Macroglobulinemia.

Meletios Dimopoulos, University of Athens, Greece

WM041 ASPEN Biomarker analysis: Response to BTK inhibitor treatment in patients with Waldenstrom Macroglobulinemia harboring CXCR4, TP53, and TERT mutations.

Constantine Tam, Peter MacCallum Cancer Center, Australia

WM024 Identification of robust predictors for ibrutinib response by multi-omic genomics in MYD88 mutated Waldenstrom’s Macroglobulinemia.

Kris Richardson, Dana Farber Cancer Institute, USA

[15:15] Panel Discussion, All Session XI Speakers

[15:30-16:00] Afternoon Break

[16:00-17:15] Session: XII

Management of covalent BTK-inhibitor exposed patients

Shayna Sarosiek, Carlos De Larrea [Chairs]

Dose reduction of ibrutinib and impact on treatment course

Shayna Sarosiek, Dana Farber Cancer Institute, USA

Zanubrutinib in patient’s intolerant to ibrutinib/acalabrutinib

Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA

Venetoclax in Previously Treated WM incl. BTK-inhibitor exposed patients

Jorge Castillo, Dana Farber Cancer Institute, USA

Pirtobrutinib in Previously Treated WM Patients with Covalent BTK-inhibitor

1. L. Palomba, Memorial Sloan Kettering Cancer Center, USA

MK-1026 Dose Expansion Study in B-cell malignancies incl WM

Deborah Stephens, University of Utah, Huntsman Cancer Institute, USA

[17:00] Panel Discussion, All Session XII Speakers

[17:15-17:45] Keynote Lectures

Mechanistic Insights into Adverse Events underlying BTK-inhibitors

Keynote Speaker: C.I. Edvard Smith, Karolinska Institut, Sweden

Targeting the Epigenome: Opportunities for WM

Keynote Speaker: Ari Melnick, Cornell University, USA

[17:45] Day Adjournment

[18:30] Faculty Dinner Reception

[8:00-11:15] Session XIII

Great Debates in WM

Eva Kimby, Jesus San Miguel [Chairs]

[8:00-8:30] Great Debate I

Should we treat smoldering WM? -No

Prashant Kapoor, Mayo Clinic, USA

Should we treat smoldering WM? -Yes

Irene Ghobrial, Dana Farber Cancer Institute

[8:30-9:00] Great Debate II

Should BTK-I or Benda-R be the standard frontline induction regimen? -for Benda-R

Christian Buske, University Hospital Ulm, Germany

Should BTK-I or Benda-R be the standard frontline induction regimen? -for BTK-I

Meletios Dimopoulos, University of Athens, Greece

[9:00-9:45] Great Debate III

Does the choice of BTK-inhibitor matter? -for Ibrutinib

Ranjana Advani, Stanford University Medical Center, USA

Does the choice of BTK-inhibitor matter? -for Acalabrutinib

Roger Owen, Leeds Hospital NHS Trust, UK

Does the choice of BTK-inhibitor matter? -for Zanubrutinib

Judith Trotman, University of Sydney, Australia

[9:45-10:15] Morning Break

[10:15-10:45] Great Debate IV

Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Dose reduce

M Lia Palomba, Memorial Sloan Kettering Cancer Center, USA

Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Switch

Alexandra Tedeschi, Niguarda Hospital, Italy

[10:45-11:15] Great Debate V

What should be the end point of therapy in WM? -Disease control should be the endpoint of therapy

Stathis Kastritis, University of Athens, Greece

What should be the end point of therapy in WM? -CR should be the endpoint of therapy

Jorge Castillo, Dana Farber Cancer Institute, USA

[11:15-12:15] Session XIV

Novel Treatment Approaches to WM-Clinical I

Sheeba Thomas, Moshe Gatt [Chairs]

Venetoclax in combination with ibrutinib for WM

Jorge Castillo, Dana Farber Cancer Institute, USA

Targeting mutated CXCR4 in WM

Steven Treon, Dana Farber Cancer Institute, USA

Obinutuzumab and Idelalisib in WM

Véronique Leblond, Hôpital Pitié Salpêtrière, France

Acalabrutinib and Rituximab for WM and IGM RD PN

Shayna Sarosiek, Dana Farber Cancer Institute, USA

[12:00] Panel Discussion, All Session XIV Speakers

[12:15-13:00] Session XV

Novel Treatment Approaches to WM-Clinical II

Jorge Castillo, Stephen Ansell [Chairs]

Tirabrutinib in Treatment Naïve and Previously Treated WM

Koji Izutsu, National Cancer Center Hospital, Japan

Phase II study of Orelabrutinib in relapsed/refractory WM

Xinxin Cao, Peking Union Medical College, China

Clinical Activity of IRAK4 Inhibitor CA-4948 in NHL, incl. WM

Reinhard Von Roemeling, Curis Pharmaceuticals, USA

[12:50] Panel Discussion, All Session XV Speakers

[13:00-14:00] LUNCH

[14:00-15:00] Session XVI

Novel Treatment Approaches to WM-Clinical III

Merav Leiba, Shirley D’Sa [Chairs]

Bispecifics in WM-CD3XCD20 RGN1979

Stephen Ansell, Mayo Clinic, USA

Phase II Study of Loncastuximab in WM

Shayna Sarosiek, Dana Farber Cancer Institute, USA

Idiotype DNA Vaccine Therapy for WM

Sheeba Thomas, MD Anderson, USA

CD20 CAR-T therapy for WM and other B-NHLs

Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA

[14:45] Panel Discussion, All Session XVI Speakers

[15:00-15:30] Keynote Lectures

Bi-specifics and Conjugated Antibodies: MM Experience

Keynote Speaker: Kenneth C. Anderson, Dana Farber Cancer Institute, USA

Bringing CART to WM: Which One?

Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA

[15:30-16:00] Afternoon Break

[16:00-16:45] Session XVII

Special Topics Lectures

Clinical Characteristics and Outcomes with Cryoglobulinemia in WM

Speaker: Shirley D’Sa, UC London Hospitals NHS, UK

Clinical Characteristics and Outcomes with Cold Agglutinins in WM

Speaker: Josephine Vos, University of Amsterdam, Netherlands

Management of Amyloidosis in WM Patients

Speaker: Giampaolo Merlini, University of Pavia, Italy

[16:35] Panel Discussion, All Session XVII Speakers

[16:45] Day Adjournment

[18:30] Dinner Reception and Closing Ceremonies

• Keynote Speaker: Meletios Dimopoulos, MD

Challenges of WM Patient Care in the Era of Covid

• Presentation of Peter S. Bing Humanitarian Awards
• Presentation of Jan Gosta Waldenstrom Awards
• Announcement and Welcome to IWWM-12

[8:00-9:15] Session XVIII

COVID and WM

Ramón García Sanz, Andrew Branagan [Chairs]

Responses to COVID vaccination in WM and MM Patients

Andrew Branagan, Massachusetts General Hospital, USA

Responses to COVID vaccination (initial and booster dose) in patients with plasma cell neoplasms

Evangelos Terpos, University of Athens, Greece

GETH-TC Study on Serological responses to initial vaccination and booster in heme patients

with /without prior COVID19

Ramón García-Sanz, University of Salamanca, Spain

Efficacy of BNT162b2 in WM and FLL -Australian Experience

Judith Trotman, University of Sydney, Australia

Impact of Booster Vaccination on SARS-COV-2 Antibody Levels in Blood CA Patients incl. WM

Lee Greenberger, Leukemia Lymphoma Society, USA

[9:00] Panel Discussion, All Session XVIII Speakers

[9:15-9:45] Session XIX

Clinical Trials in Progress

Constantine Tam, Efstathios Kastritis [Chairs]

European Trials in Progress

M.J. Kersten, UMC Medical Center, University of Amsterdam, Netherlands

North American Trials in Progress

Jorge Castillo, Dana Farber Cancer Institute, Boston MA USA

[9:45-10:00] Morning Break

[10:00-13:00] Session XX

WM Panel Discussions and Sunday Brunch

Addressing the Key Questions in WM Management

Steve Treon, Meletios Dimopoulos [Moderators]

WM Consensus Panel I

IWWM-11 Recommendation for Treatment Approach in WM-Frontline

Organizers: Christian Buske, Jorge Castillo, Judith Trotman

WM Consensus Panel II  

IWWM-11 Recommendation for Treatment Approach in WM-Relapsed/Refractory

Organizers: Efstathios Kastritis, Shirley D'SA, Jeffrey Matous

WM Consensus Panel III  

IWWM-11 Recommendation for Molecular Diagnostic Workup in WM

Organizers: Ramón García-Sanz, Marzia Varettoni, Zachary Hunter

WM Consensus Panel IV  

Response Criteria for WM

Organizers: Steve Treon, Roger Owen, Alessandra Tedeschi

WM Consensus Panel V  

COVID Prophylaxis and Management in WM

Organizers: Meletios Dimopoulos, Véronique Leblond, Andrew Branagan

WM Consensus Panel VI  

Management of WM-related Amyloidosis

Organizers: Monique Minnema, Shayna Sarosiek, Giampaolo Merlini

WM Consensus Panel VII  

Priorities for Novel Clinical Trials

Organizers: MJ Kersten, Prashant Kapoor, Constantine Tam

[13:30] Meeting Adjournment